{"title":"CROI 2025：艾滋病毒感染者的结核病、Mpox和其他感染并发症。","authors":"Andrew D Kerkhoff, Jason Zucker, Diane V Havlir","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Updated strategies and new insights into tuberculosis and mpox treatment were a major focus at the 2025 Conference on Retroviruses and Opportunistic Infections, headlined by findings that high-dose rifampicin plus levofloxacin increased early mortality in hospitalized people with HIV with disseminated tuberculosis, whereas tecovirimat demonstrated no efficacy for clade II mpox. Herein, we summarize clinically relevant updates related to tuberculosis, mpox, Kaposi sarcoma, human papillomavirus, and other HIV-associated infectious complications presented at the conference.</p>","PeriodicalId":38738,"journal":{"name":"Topics in antiviral medicine","volume":"33 2","pages":"494-507"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CROI 2025: tuberculosis, Mpox, and other infectious complications in people with HIV.\",\"authors\":\"Andrew D Kerkhoff, Jason Zucker, Diane V Havlir\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Updated strategies and new insights into tuberculosis and mpox treatment were a major focus at the 2025 Conference on Retroviruses and Opportunistic Infections, headlined by findings that high-dose rifampicin plus levofloxacin increased early mortality in hospitalized people with HIV with disseminated tuberculosis, whereas tecovirimat demonstrated no efficacy for clade II mpox. Herein, we summarize clinically relevant updates related to tuberculosis, mpox, Kaposi sarcoma, human papillomavirus, and other HIV-associated infectious complications presented at the conference.</p>\",\"PeriodicalId\":38738,\"journal\":{\"name\":\"Topics in antiviral medicine\",\"volume\":\"33 2\",\"pages\":\"494-507\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Topics in antiviral medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Topics in antiviral medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
CROI 2025: tuberculosis, Mpox, and other infectious complications in people with HIV.
Updated strategies and new insights into tuberculosis and mpox treatment were a major focus at the 2025 Conference on Retroviruses and Opportunistic Infections, headlined by findings that high-dose rifampicin plus levofloxacin increased early mortality in hospitalized people with HIV with disseminated tuberculosis, whereas tecovirimat demonstrated no efficacy for clade II mpox. Herein, we summarize clinically relevant updates related to tuberculosis, mpox, Kaposi sarcoma, human papillomavirus, and other HIV-associated infectious complications presented at the conference.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
